In vivo activity of interleukin-2: conversion of a stimulus causing unresponsiveness to a stimulus causing contact hypersensitivity by the injection of interleukin-2.
The intravenous injection of hapten-modified (picrylated) cells causes unresponsiveness. When conventional or recombinant interleukin-2 (IL-2) is also injected, strong contact sensitivity occurs. This IL-2 is effective when given 7 hr after the injection of the picrylated cells or 2 days later, but has no effect when given beforehand. It is suggested that picrylated cells given intravenously fail to induce contact sensitivity secondary to a failure of IL-2 production, and that IL-2 may be one of the second signals which converts a 'tolerogenic' stimulus into an immunogenic stimulus.
D000818:Animals; D003877:Dermatitis, Contact / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007108:Immune Tolerance; D007116:Immunization, Passive; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology*; D007700:Kinetics; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D013154:Spleen / Q000276:immunology; D013997:Time Factors; D014302:Trinitrobenzenesulfonic Acid / Q000276:immunology
D007376:Interleukin-2; D014302:Trinitrobenzenesulfonic Acid